ReportWire

Tag: SLN

  • Does Lizzo Consume Weed

    Does Lizzo Consume Weed

    [ad_1]

    She has won Grammys and awards from BET, BillBoard and more while redefining enticing. But does she consume weed?

    She burst into the mainstream in 2019 with her third studio album, Cuz I Love You and has been making waves ever since. Resetting standards of how a female music star needs to look and behave, she has been the center of ongoing dissuasions.  Through all this, you wonder does Lizzo consume weed to chill and relax. She has attracted legends of fans called Lizzbians, a number of social media trolls and Grammys, BET awards, Billboards Awards and appearance on SLN, Ugly Dolls, Hustlers, and more  . She rode another wave of popularity when she featured an original single titled Pink in the Barbie movie.

    RELATED: Yacht Rock Pairs Perfectly With Cocktails

    She started her career in hip hop music. After doing a couple of studio albums, she signed with  with Nice Life Recording Company and Atlantic Records releasing Coconut Play.The album spawned the singles Juice and Tempo. The deluxe version of Cuz I Love You topped the US Billboard Hot 100 and became the longest-leading solo song by a female rapper. In 2021, Lizzo released the single Rumors (featuring Cardi B), which debuted in the top five of the Billboard Hot 100. Her fourth studio album, Special (2022), was preceded by its lead single “About Damn Time“, which reached number one on the Billboard Hot 100 and made Lizzo the first black female singer since Whitney Houston in 1994 to win the Grammy Award for Record of the Year.

    Like everything in her life it seems, she is unabashed about her use of marijuana. Her Instagram shares she is on a fan consuming and treats it just like drinking wine. She has even been cheeky about her use including wink wink tweets about marijuana suppositories.

    RELATED: How To Be Discreet When Using Weed

    Lizzo grew up attending the Church of God in Christ but has since embraced a more open concept where she sings hip hop mixed with soul and blues. Lizzo being so open about herself and weed use is similar to the late Mama Cass, who refined talent, fun and what is like to be a celebrity.

     

    [ad_2]

    Anthony Washington

    Source link

  • Silence Therapeutics (NASDAQ:SLN) and Corvus Pharmaceuticals (NASDAQ:CRVS) Financial Contrast

    Silence Therapeutics (NASDAQ:SLN) and Corvus Pharmaceuticals (NASDAQ:CRVS) Financial Contrast

    [ad_1]

    Silence Therapeutics (NASDAQ:SLNGet Rating) and Corvus Pharmaceuticals (NASDAQ:CRVSGet Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

    Insider and Institutional Ownership

    47.5% of Corvus Pharmaceuticals shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 29.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

    Profitability

    This table compares Silence Therapeutics and Corvus Pharmaceuticals’ net margins, return on equity and return on assets.

    Net Margins Return on Equity Return on Assets
    Silence Therapeutics -222.79% -361.62% -37.16%
    Corvus Pharmaceuticals N/A -49.08% -42.46%

    Valuation & Earnings

    This table compares Silence Therapeutics and Corvus Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
    Silence Therapeutics $17.07 million 28.26 -$54.19 million ($1.52) -8.84
    Corvus Pharmaceuticals N/A N/A -$43.24 million ($0.88) -0.91

    Corvus Pharmaceuticals has lower revenue, but higher earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

    Analyst Recommendations

    This is a summary of current recommendations and price targets for Silence Therapeutics and Corvus Pharmaceuticals, as reported by MarketBeat.com.

    Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
    Silence Therapeutics 0 1 2 0 2.67
    Corvus Pharmaceuticals 0 0 3 0 3.00

    Silence Therapeutics currently has a consensus price target of $42.33, indicating a potential upside of 214.98%. Corvus Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 400.00%. Given Corvus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Silence Therapeutics.

    Volatility & Risk

    Silence Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

    Summary

    Corvus Pharmaceuticals beats Silence Therapeutics on 10 of the 13 factors compared between the two stocks.

    About Silence Therapeutics

    (Get Rating)

    Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company’s platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body’s natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence’s mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

    About Corvus Pharmaceuticals

    (Get Rating)

    Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

    Receive News & Ratings for Silence Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Silence Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link